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Approaches to Assessing Genetic Risks from
Exposure to Chemicals
by F. H. Sobels
An effort to assess and quantify genetic risks from human exposure to mutagenic chemicals is urgently
needed; otherwise genetic toxicology may well lose its credibility. Genetic biomonitoring provides us with an
indication ofmutagenic effectiveness in human somatic cells.Thepopulations andchemicals selectedforsuch
studies form a useful database for genetic risk-assessment studies. Extrapolation to what can be expected in
germ cells ofexposed individuals should be possible by using good dosimetry (adducts) and a parallelogram
approach. The principle is that genetic damage in the inaccessible human germ cells can be estimated by
determining the effects on lymphocytes (or other somatic cells) from humans and mice and in germ cells of
mice. Worldwide, opportunities for the costly mouse germ cell studies are limited. Knowledge oftype ofDNA
adducts, their persistence and/or removal and dominant lethal studies, will be helpful in predicting stage
sensitivity. Extrapolation from a lowest effective dose level is proposed. The available data for ethylene oxide
and benzene are reviewed. The risk ofheritable translocations in progeny ofpopulations exposed to ethylene
oxide is so high that more precise estimates seem desirable. In discussing the expression of the induced
mutations,the importance ofdominantmutationsandofheterozygous effectsofdeletionsandotherrecessives
is pointed out. The molecular changes underlying dominant mutations in man are more limited than is the
case for recessive mutations. This raises the question whether mutagenic agents can produce the specific
changes leading to recoverable, dominant mutations. Extrapolation from increased mutation rates to
predictable increases ofhuman disease, whether by doubling dose or direct methods, have been criticized.
Introduction
It is a well-known fact that about 10.5% of all live-born
children are burdened with a disease or malformation of
genetic etiology; thishigh naturalburdenwillundoubtedly
increase from exposure to mutagenic agents. Conse-
quently, hereditary damage should play an importantpart
in our concern regarding the genetic effects ofchemicals.
In contrast to chemically induced cancer in man, genetic
diseases or abnormalities resulting from mutations
induced in human germ cells have not yet been detected.
An effort to assess and quantify genetic risks resulting
from human exposure to mutagenic chemicals is urgently
called for; otherwise genetic toxicologists may well lose
credibility.
Genetic Biomonitoring and the
Parallelogram
Biomonitoring provides us with a first indication of
mutagenic effectiveness of aparticular chemical exposure
in human somatic cells. The chemicals and populations
Department ofRadiation Genetics and Chemical Mutagenesis, Sylvius
Laboratory, Leiden University, P.O. Box 9503, Wassenaarseweg 72, 2300
RA Leiden, The Netherlands.
selected for genetic biomonitoring should receive priority
in studies ontheassessmentofgeneticrisk. Inpopulations
exposed to complex mixtures, molecular analysis of the
induced mutations may help identify the most mutagenic
components. Extrapolation to what can be expected in
germ cells oftheexposed individuals shouldbepossibleby
using good dosimetry and aparallelogram approach [Fig.
1 (1-3)]. Briefly, this approach is based on the principle
that genetic damage which cannot be measured directly,
such as that in human germ cells, can be estimated by
measuringthe samekindofdamageinbothgermcellsand
somaticcells ofthemouse. Ifwehave data ontheinduction
ofmutations orchromosomeaberrationsinbothgermcells
and somatic cells of the mouse, one would hope that this
relationship would make it possible to estimate germ cell
mutationfrequencies in man on thebasis ofwhathas been
measured inmonitoringgenetic damagein human somatic
cells. The underlying assumption is, of course, that the
quantitative relationshipbetweendamageinducedingerm
cells and somatic cells and theircapacityforrepair are not
vastly different between mouse and man.
For those chemicals forwhich data on genetic effects in
human somatic cells are available, I would favor research
to obtain data on the induction ofmutations and/or chro-
mosomal aberrations in mouse germ cells in association
with studies to measure the same kind of damage inF. H. SOBELS
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FIGURE 1. The principle ofthis parallelogram is that genetic damage in
human germ cells canbe estimated bymeasuringacommon endpointin
humans and mice, such as mutations or chromosomal aberrations in
lymphocytes, andacorrespondinggeneticendpointingermcellsofmice,
the desired target tissue inaccessible in man. Appropriate dosimetry
should be carried out by the concomitant measurement ofadducts (2,3).
somatic cells of the mouse. First, one would need to
ascertainwhetherthe selected chemical reaches the germ
cells and interacts bythe formation ofadducts with germ
cell DNA. Ifthekinds ofDNAadducts are known, certain
predictions forgerm cell mutagenesis inthe mouse canbe
made(4,5). Inshort,genotoxinswithpreferenceforalkyla-
tion of nitrogen atoms (SN2 mechanism) are effectively
repaired in cells with efficient error-free repair, such as
mouse spermatogonia. This appears to be the reason
genotoxins such as diethyl sulfate, ethyl methane sulfo-
nate, methyl methane sulfonate, ethylene oxide, and
acrylamidefailedtoproducemutationsinearly-stagemale
germcells ofthemouse (6,7). Intheabsenceofrepair, such
agents are highly effective genotoxins, particularly by
producing chromosome breakage (8,9). In the mouse, all
theseagentsareeffectivemutagensinlatespermatidsand
in spermatozoa that have lost the capacity for repair. On
the basis of Drosophila data, one would expect that the
mutations induced would mainly consist of transversions
anddeletions. Mutagenswithlows(Swain-Scottconstant)
like ethylnitrosourea and diethylnitrosamine predomi-
nantly alkylate oxygen atoms (SN1 mechanism), such as
the 06 position of guanine and the 04 ofthymine. These
lesions are slowlyrepaired, andthatiswhytheyhavehigh
mutagenic and carcinogenic potency. They produce base
GC to AT and AT to GC transitions, respectively.
Dominantlethal studiesmayhelpdefine experimentally
themostsensitive germcellstage (10). Inviewofcostsand
labor involved with specific locus and heritable transloca-
tion studies, dose settingmerits someconsideration. Real-
istic conditions ofhuman exposure most probably involve
doses too low to measure genetic effects in the mouse.
Linear extrapolation from the lowest effective dose level,
assuming absence of repair, is the most conservative
assumption. End points that can conveniently be mea-
sured in somatic cells, like micronuclei or hprt mutations,
should be useful for selecting the appropriate dose levels
(11).Thedetermination ofdose-effect curves atdoselevels
higher than the lowest effective dose in mouse germ cells
maybe less desirable ifconsidered on a cost/benefit basis.
Itmaybe noted thatendpoints representingchromosome
breakage phenomena, such as dominant lethals in germ
cells and micronuclei in somatic cells, are probably most
convenient for defining the lowest effective dose. This
raises the question ofwhether such data are representa-
tive for point mutations. From the pioneering studies by
Vogel (8,9) in Drosophila, we know that agents preferen-
tially alkylating nitrogen atoms are far more effective in
breaking chromosomes than those preferentially alkylat-
ing oxygen. Comparative studies in mammals for various
classes ofagents on the capacity to induce mutations, say,
inthespottest,andchromosomebreakage seemofconsid-
erable interest. It would seem that measurement of gen-
otoxic adducts in the mouse and in the exposed human
populations may be more helpful in defining margins of
safety. Datathathavebeenexplicitlycollected to achieve a
parallelogram kind of comparison are at present not yet
available. For some chemicals like ethylene oxide and
benzene, there are fairly extensive data, which I now
briefly review.
Ethylene Oxide
In a large collaborative study, Tates et al. (11) recently
reported results on hospital and factoryworkers occupa-
tionally exposed to ethylene oxide in the former German
Democratic Republic. Dosimetrywascarried outbydeter-
mining hemoglobin adducts [N-(2-hydroxyethyl)valine-
(HOEtVal)]. Factoryworkers received an estimated daily
exposure of 13.2 nmole HOEtVal per gram hemoglobin
(Hb). This value corresponds to a 40-hr time-weighted
average (TWA) of5 ppm ethylene oxide. With an average
exposurefor12years at240daysperyearand8hrperday,
the total exposure time is 12 x 240 x 8 = 23,040 hr to 5
ppmandthe doseis115,200ppm.hour. Frequenciesofcells
with high frequencies of sister chromatid exchanges
(SCEs) were enhanced by almost 2000%; chromosomal
aberrations by 260%, micronuclei by 217%, and hprt
mutantsby60%. Therelativesensitivityofthevariousend
pointsforthedetectionofethylene oxideexposureisinthe
followingorder:HOEtValadducts > SCEs > chromosomal
aberrations > micronuclei > HPRTmutants. Inviewofthe
factthatethylene oxide is atypical SN2 type ofalkylating
agent, the prevalence ofprotein alkylation is in line with
the expectation (13).
The higher sensitivity ofthe valine adducts and SCEs
has been confirmed in a large, recent study by Schulte et
al. (14) on U.S. and Mexican workers exposed to lower
dosesofethyleneoxide (EtO)withintheU.S. Occupational
Safetyand HealthAdministration standard of1 ppm8-hr
TWA.According to an estimate ofthe U.S. Departmentof
Labor(14), intheUnited Statesalone,224,000workers are
exposed to EtO.
Theliterature onthegeneticeffects ofEtO hasrecently
been reviewed by Dellarco et al. (15), and genetic risk
assessments were reported by Dellarco and Farmlandt
(16), Rhombergetal. (17), and Dellarco etal. (18). The data
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ofGeneroso et al. (19) for the induction ofheritable trans-
location in the mouse were used. Translocations increased
with a higher power ofthe dose than simple dose-squared
(17,19). Here I assume that at low doses, the two breaks
requiredfortheformation ofatranslocation areformedby
one event, and thus use linear extrapolation from the
lowest dose point. Generoso et al. (10) were able to show
that the response in males is restricted to late spermatids
and early spermatozoa, in line with other SN2-type gen-
otoxins. The period of 10 days in male mice would corre-
spond to approximately 21 days in humans (17). Different
species ofmammals show the same number ofadducts at
corresponding exposure levels. This species equivalence is
ofobviousimportance, thoughwe do notyetknowwhether
the same frequencies of genetic changes are induced at
corresponding adduct levels. If the human window of
susceptibility is chosen to be 21 days, 120 hr of exposure
are to be counted (3 weeks x 5 days perweek x 8 hr per
day). With an exposure of 10 ppm, the excess risk of
fatheringatranslocation carrierwouldbeabout5per1000
live-births (17). GaschromatographydataobtainedinEast
Germany suggest exposure levels of 33 ppm in the past
and of 17 ppm from 1989 onwards. The associated trans-
location risks would have been about 1.5% ofbirths before
1989 and of0.75% sincethen.Withabackground incidence
of19 translocation carriers per10,000 livebirths (17), EtO
exposure before 1989 has increased the risk by 750% and
half ofthat after 1989.
Benzene
To integrate mutagenicity data into risk assessment
procedures, Legator and Ward (20) advocate a multiple
end point approach in vivo at realistic exposure levels.
Benzene is cited as a case study. Cytogenetic monitoring
ofbenzene-exposed workers established alowestobserved
effect level in the range of1-10 ppm (21). These exposure
levels induce both micronuclei and SCEs in hematopoietic
cells ofrodents. Recent studies likewise show an increase
in the frequency ofhprt mutants in spleen lymphocytes of
CD-1mice(20,22), andthiswasparalleledbyanincreasein
chromosome aberrations. A nearly linear response was
reported for micronuclei in rats and mice, mutation induc-
tion, and chromosome aberrations in lymphocytes. It is of
interestthathprtmutations are amore sensitive endpoint
than chromosomal damage. There are some indications of
genotoxic effects of benzene in germ cells, though the
present data do not yet permit a parallelogram approach
to quantify the expected damage.
Extrapolation from Increased Mutation
Rates to Adverse Health Effects
The final aim ofany genetic risk assessment consists of
converting an estimated increase in mutation rate in
adverseeffects onhumanhealth.Twokindsofmethods are
usuallyemployed: thedoublingdosemethod andthedirect
method. With the doubling dose method, the damage is
expressed as an increase relative to the natural load of
genetic disease and malformations. It has the advantage
that mutational damage is expressed as excess cases of
known genetic disease, i.e., tangible human suffering. The
validity of the use of the doubling dose method rests on
various assumptions, such as a) the damage to the genetic
material resulting from exposure to mutagenic agents is
similar in nature to mutations arising spontaneously, and
b) there is a proportionality between spontaneous and
induced mutations. These assumptions become unlikely in
the light of recent findings on the molecular nature of
spontaneous and induced mutations (23,24).
With the direct method, dominant mutations affecting
the skeleton and the opacity of the eye (cataracts) are
measured in mice. Using a number ofassumptions, these
induced frequencies ofdominant mutations are translated
into an expected increase of the total load of dominant
genetic disease in man. The idea that the probability of
inducingadominantdiseaseaffectinganybodilysystemis
a simple multiple ofthe rate ofinduction ofeither skeletal
or cataract mutations in the model system has been criti-
cized (24,25). Sankaranarayanan's (24) argument is that
the selected genes with dominant expression are flexible;
that is, they have less functional constraints (see below),
and it is not known whether they are representative ofall
genes at which dominant mutations arise.
In estimating the impact on human health of an
increasedfrequencyoftranslocations, adirectapproachis
also possible. In mice, heritable translocations induced by
chemical mutagens are sometimes associated with neu-
rological disorders, blindness, and skeletal abnormalities
(26,27). In humans, cases are knownwhere translocations
are associated with skeletal abnormalities and various
other conditions. Thus, translocation carriers have an
increased risk of having a serious medical disorder, and
one should realize that these are transmitted as simple
Mendelian dominants. In addition, halfofthe gametes ofa
translocationcarriercontainunbalanced,aneuploid segre-
gants. Rutledge et al. (27) found a high incidence of
developmental anomalies in mice, as exencephaly and cleft
palate among descendants of translocation carriers.
Although the majority of these unbalanced zygotes will
lead to stillbirths in man, 6% of these are assumed to
result in congenitally malformed children (28). We have
seen before that the exposure to 33 ppm EtO will increase
the incidence oftranslocation carriers, from abackground
of19 per10,000, to 150 per 10,000. Apart from the possible
damage expressed in the carriers, these are expected to
produce 300 per 10,000 unbalanced products, ofwhich 6%,
or18per10,000, livebirthswillbecongenitallymalformed.
In the populations exposed to EtO in East Germany,
exposures have lasted 12 years on average. It is obvious
that the risk of heritable translocation in the progeny of
these populations is far from negligible. Consequently,
morepreciseestimatesbased on aparallelogramapproach
would seem desirable. These could be obtained by compar-
ing genetic end points in germ cells and somatic cells of
mice to measurements of EtO adducts.
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Problems in Mammalian Mutation
Studies
An assessment ofrisks associated with the induction of
mutations is not yet possible on the basis ofthe available
mouse data. The difficulties encountered in obtaining
appropriate mutation data from mouse germ cells can be
illustrated bythe available observations with EtO. Russell
et al. (29) carried out a large-scale, specific locus study in
which atotal of71,387 progenywere scored after exposure
of male mice to high doses of EtO. No significant dif-
ferences with historical control frequencies were
observed. Lewis et al. (26) reported more positive results
for electrophoretic and dominant mutations. It is assumed
thatthesemutations areprimarilyderivedfrompost-stem
cells because ofthe negative findings for stem cells in the
study by Russell et al. (29).
The paucity ofdata, the expenses involved, and the fact
that there are only a few laboratories in the world where
such studies can be carried out pose serious problems in
genetic risk assessment studies. Future work with trans-
genic mice may be helpful in this respect. A database in
which the nature and frequency of mutations induced in
the germ cells and in somatic cells of normal mice are
compared with what can be measured from the same cells
and organs oftransgenic mice maymakeitpossible, inthe
future, to usetransgenic mice directlyforrisk assessment
studies, thereby, at least in part, circumventing the time-
consuming and costly mouse mutation studies.
Expression of Mutations
The question of how mutations are expressed is of
obvious importance. Mutations with a purely recessive
mode ofinheritance are not a matter ofprimary concern
because it takes many generations before they are
expressed through homozygosity. This is also the reason
estimation ofgenetic risks either directly or by the doub-
ling dose method is focused on simple Mendelian domi-
nants. Recessive mutations are induced at considerably
higher frequency than dominant ones; thus, even small
effects in heterozygous condition of mutations with an
apparent recessive mode of inheritance are important
when estimating adverse effects on human health. In
terms ofdeleterious effects in the heterozygous condition,
multilocus deletions are of greater significance than
single-site mutations. This observation has recently been
demonstrated in the mouse, Neurospora, and Drosophila
(30-34).
Well-characterized, multilocus deletions at different
sites on the X-chromosome ofDrosophila almost all lower
viability in heterozygous condition [Fig. 2 (34)]. Genes
essential for heterozygous viability are obviously missing
in the deleted regions. Consequently, in terms of compar-
ing genetic risks resulting from exposure to different
kinds of mutagenic agents, those producing multilocus
deletions should receive priority (35,36), such as cross-
linking agents like hexamethyl phosphoramide (HMPA)
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FIGURE 2.Theviabilityinfemales heterozygous fordeletions ofthesame
size at different sites on theX-chromosome ofDrosophila. It can be seen
that almost all deletions lower viability in comparison to the controls
(1.00) (34).
only produce deletions (Aquirrezabalaga et al., personal
communication). In this respect, ionizing radiation is the
prime example of an agent predominantly inducing dele-
tions. Infact, mostofthegenelociatwhich suchmutations
have been studied are nonessential for survival (24,37,38).
Deletions inheterozygous conditionlowerviability,bothin
Drosophila and Neurospora. How this kind of damage is
expressed in man and could possibly be quantified, we do
not know. More than 40 years ago, Muller (39) stated that
these deleterious changes in heterozygous condition will
decrease the overall viability and fitness of an individual,
will reduce life span, and will make the individual more
susceptible to infectious disease.
What can one now say about recessive and dominant
mutations in man? A recent reviewby Sankaranarayanan
(40) hasrevealed anumberofinterestingfacts. Ingeneral,
itwas noted thatmutations in genes thatcode forenzymic
proteins are mostly recessive, as, for example, in various
inborn errors of metabolism. When a recessive mutation
first arises, itis sheltered bythe dominantwild-type allele
in the heterozygote; thatis, halfthe enzymic activityis on
the whole sufficient for normal functioning. Therefore, a
wide variety ofmolecular changes can be recovered; they
range from base-pair substitution to rearrangements,
duplications, and deletions.
For dominant mutations, however, the variety of
observed molecular changes is more limited. They occur
predominantlyingenesthatcodefornonenzymicproteins,
such as collagen. Here, halfofthe required product is not
sufficientfornormalfunctioning. Moreover, drasticaltera-
tions will be incompatible with survival, and thus the
mutations will not come to light.
In view of these functional constraints, only a limited
number ofmolecular changes leading to dominant muta-
tions are compatible with survival. The crucial question,
thus, is whether mutagenic agents are capable ofproduc-
ing the specific changes leading to recoverable dominant
mutations (i.e., dominantmutationsknowntobeinvolvedin
thecausationofhumandisease). Thecomingyearswill see
spectacular progress in the molecular analysis of human
genetic disease, in particular through the coordinated
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effort in the Human Genome Project. Comparison to the
molecular changes leading to genetic diseasewith specific
patterns of molecular change induced by the mutagens
under study may in the future help to circumvent the
problems with extrapolating from induced mutation to
human disease.
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